HRP20230344T1 - Protutijela protiv sortilina i postupci njihove upotrebe - Google Patents
Protutijela protiv sortilina i postupci njihove upotrebe Download PDFInfo
- Publication number
- HRP20230344T1 HRP20230344T1 HRP20230344TT HRP20230344T HRP20230344T1 HR P20230344 T1 HRP20230344 T1 HR P20230344T1 HR P20230344T T HRP20230344T T HR P20230344TT HR P20230344 T HRP20230344 T HR P20230344T HR P20230344 T1 HRP20230344 T1 HR P20230344T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- sortilin
- amino acid
- disease
- acid sequence
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 8
- 102100032889 Sortilin Human genes 0.000 claims 7
- 108010014657 sortilin Proteins 0.000 claims 7
- 101000868139 Homo sapiens Sortilin Proteins 0.000 claims 6
- 102000019204 Progranulins Human genes 0.000 claims 6
- 108010012809 Progranulins Proteins 0.000 claims 6
- 208000027418 Wounds and injury Diseases 0.000 claims 5
- 230000006378 damage Effects 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 208000014674 injury Diseases 0.000 claims 5
- 238000006467 substitution reaction Methods 0.000 claims 5
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 3
- 230000003993 interaction Effects 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 206010010904 Convulsion Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 208000032578 Inherited retinal disease Diseases 0.000 claims 2
- 201000007737 Retinal degeneration Diseases 0.000 claims 2
- 208000032430 Retinal dystrophy Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 102000004584 Somatomedin Receptors Human genes 0.000 claims 2
- 108010017622 Somatomedin Receptors Proteins 0.000 claims 2
- 108010033576 Transferrin Receptors Proteins 0.000 claims 2
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 201000006321 fundus dystrophy Diseases 0.000 claims 2
- 208000017532 inherited retinal dystrophy Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000004258 retinal degeneration Effects 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 235000002198 Annona diversifolia Nutrition 0.000 claims 1
- 206010053555 Arthritis bacterial Diseases 0.000 claims 1
- 102100032412 Basigin Human genes 0.000 claims 1
- 108010064528 Basigin Proteins 0.000 claims 1
- -1 CD98hc Proteins 0.000 claims 1
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims 1
- 101100393884 Drosophila melanogaster Glut1 gene Proteins 0.000 claims 1
- 102000018710 Heparin-binding EGF-like Growth Factor Human genes 0.000 claims 1
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 claims 1
- 208000004575 Infectious Arthritis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102000003746 Insulin Receptor Human genes 0.000 claims 1
- 108010001127 Insulin Receptor Proteins 0.000 claims 1
- 241000282842 Lama glama Species 0.000 claims 1
- 101710172064 Low-density lipoprotein receptor-related protein Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 101150058068 SLC2A1 gene Proteins 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 210000003050 axon Anatomy 0.000 claims 1
- 230000007845 axonopathy Effects 0.000 claims 1
- 230000008499 blood brain barrier function Effects 0.000 claims 1
- 210000001218 blood-brain barrier Anatomy 0.000 claims 1
- GBVKRUOMSUTVPW-AHNVSIPUSA-N chembl1089636 Chemical compound N([C@H]([C@@H](OC(=O)CCC(=O)N[C@@H](C(O)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@H]([C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@H]([C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 GBVKRUOMSUTVPW-AHNVSIPUSA-N 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000004777 loss-of-function mutation Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 108010046239 paclitaxel-Angiopep-2 conjugate Proteins 0.000 claims 1
- 108010043655 penetratin Proteins 0.000 claims 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 108010011110 polyarginine Proteins 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 201000001223 septic arthritis Diseases 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Claims (36)
1. Protutijelo koje se veže na protein ljudski sortilin, pri čemu protutijelo sadrži varijabilno područje teškog lanca, koje sadrži aminokiselinski slijed SEQ ID NO: 56, i varijabilno područje lakog lanca, koje sadrži aminokiselinski slijed SEQ ID NO: 60.
2. Protutijelo koje se veže na protein ljudski sortilin, pri čemu protutijelo sadrži varijabilno područje teškog lanca, koje sadrži aminokiselinski slijed SEQ ID NO: 56, i varijabilno područje lakog lanca, koje sadrži aminokiselinski slijed SEQ ID NO: 57.
3. Protutijelo koje se veže na protein ljudski sortilin, pri čemu protutijelo sadrži teški lanac, koji sadrži aminokiselinski slijed SEQ ID NO: 137, i laki lanac, koji sadrži aminokiselinski slijed SEQ ID NO: 142.
4. Protutijelo koje se veže na protein ljudski sortilin, pri čemu protutijelo sadrži teški lanac, koji sadrži aminokiselinski slijed SEQ ID NO: 138, i laki lanac, koji sadrži aminokiselinski slijed SEQ ID NO: 142.
5. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 4, pri čemu protein ljudski sortilin sadrži aminokiselinski slijed SEQ ID NO: 81.
6. Protutijelo u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, pri čemu protutijelo pripada klasi IgG, klasi IgM, ili klasi IgA.
7. Protutijelo u skladu s patentnim zahtjevom 6, pri čemu protutijelo pripada klasi IgG i ima izotip IgG1, IgG2, IgG3, ili IgG4.
8. Protutijelo u skladu s patentnim zahtjevom 7, pri čemu:
(a) protutijelo pripada izotipu IgG1 ili IgG2, a područje Fc sadrži aminokiselinsku zamjenu na položaju P33 1S, pri čemu je obrojčavanje položaja ostatka u skladu s EU obrojčavanjem;
(b) protutijelo pripada izotipu IgG1, a područje Fc sadrži aminokiselinske zamjene na položajima L234A, L235A, te P331S, pri čemu je obrojčavanje položaja ostatka u skladu s EU obrojčavanjem;
(c) protutijelo pripada izotipu IgG1, IgG2, ili IgG4, a područje Fc sadrži aminokiselinsku zamjenu na položaju N297A, pri čemu je obrojčavanje položaja ostatka u skladu s EU obrojčavanjem; ili
(d) područje Fc sadrži aminokiselinsku zamjenu na položajima S267E i L328F, pri čemu je obrojčavanje položaja ostatka u skladu s EU obrojčavanjem.
9. Protutijelo u skladu s patentnim zahtjevom 8, pri čemu protutijelo pripada izotipu IgG1, a područje Fc sadrži aminokiselinske zamjene na položajima L234A, L235A, te P331S, pri čemu je obrojčavanje položaja ostatka u skladu s EU obrojčavanjem.
10. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-9, pri čemu je protutijelo ljudsko protutijelo, bispecifično protutijelo, monoklonsko protutijelo, viševalentno protutijelo, ili konjugirano protutijelo.
11. Protutijelo u skladu s patentnim zahtjevom 10, pri čemu je protutijelo bispecifično protutijelo, koje prepoznaje protein sortilin i drugi antigen.
12. Protutijelo u skladu s patentnim zahtjevom 11, pri čemu je drugi antigen antigen koji olakšava transport kroz krvno-moždanu barijeru.
13. Protutijelo u skladu s patentnim zahtjevom 12, pri čemu drugi antigen se bira iz skupine koju čine transferinski receptor (TR), inzulinski receptor (HIR), receptor čimbenika rasta sličnog inzulinu (IGFR), proteini 1 i 2 srodni receptoru lipoproteina niske gustoće (LPR-1 i 2), receptor difterijskog toksina, CRM197, jednodomensko protutijelo iz ljame, TMEM 30(A), domena transdukcije proteina, TAT, Syn-B, penetratin, poliargininski peptid, peptid angiopep, basigin, Glut1, CD98hc, te ANG1005.
14. Protutijelo u skladu s patentnim zahtjevom 1 ili 2, pri čemu je protutijelo fragment protutijela koji se veže na protein ljudski sortilin.
15. Protutijelo u skladu s patentnim zahtjevom 14, pri čemu je fragment protutijela fragment Fab, Fab’, Fab’-SH, F(ab’)2, Fv, ili scFv.
16. Izolirana nukleinska kiselina, koja sadrži nukleinskokiselinski slijed koji kodira protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-15.
17. Vektor, koji sadrži nukleinsku kiselinu u skladu s patentnim zahtjevom 16.
18. Izolirana stanica domaćin, koja sadrži vektor u skladu s patentnim zahtjevom 17.
19. Postupak proizvodnje protutijela koje se veže na sortilin, koji se sastoji u uzgoju stanice domaćina u skladu s patentnim zahtjevom 18 kako bi se proizvelo protutijelo.
20. Postupak u skladu s patentnim zahtjevom 19, koji dodatno uključuje prikupljanje protutijela kojeg proizvodi stanica domaćin.
21. Farmaceutski pripravak, koji sadrži protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-15 i farmaceutski prihvatljivi nosač.
22. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-15, namijenjeno upotrebi kao lijek.
23. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-15, namijenjeno upotrebi u postupku sprječavanja, smanjivanja opasnosti od pojave ili liječenja bolesti, poremećaja, ili ozljede, koju se bira iz skupine koju čine frontotemporalna demencija, Alzheimerova bolest, vaskularna demencija, napadaji, distrofija mrežnice, amiotrofna lateralna skleroza, traumatska ozljeda mozga, ozljeda kralježnične moždine, demencija, inzult, Parkinsonova bolest, degeneracija mrežnice, multipla skleroza, septični šok, artritis, osteoartritis i neuropatska bol.
24. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-15, namijenjeno upotrebi u postupku sprječavanja, smanjivanja opasnosti od pojave ili liječenja bolesti, poremećaja, ili ozljede, koju se bira iz skupine koju čine frontotemporalna demencija, Alzheimerova bolest, vaskularna demencija, napadaji, distrofija mrežnice, amiotrofna lateralna skleroza, traumatska ozljeda mozga, ozljeda kralježnične moždine, demencija, inzult, Parkinsonova bolest, degeneracija mrežnice, multipla skleroza, septični šok, artritis i osteoartritis.
25. Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 24, pri čemu se bolest, poremećaj, ili ozljedu, bira iz skupine koju čine frontotemporalna demencija, Alzheimerova bolest, amiotrofna lateralna skleroza, te Parkinsonova bolest.
26. Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 25, pri čemu je bolest, poremećaj ili ozljeda frontotemporalna demencija.
27. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-15, namijenjeno upotrebi u postupku sprječavanja, smanjivanja opasnosti od pojave ili liječenja upalnog poremećaja.
28. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-15, namijenjeno upotrebi u postupku inhibitiranja upale živčanog tkiva ili aksonopatije, naznačene time što je za nju karakterističan kratak aksonski izdanak i aberantno grananje kod osobe kojoj je to potrebno.
29. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-15, namijenjeno upotrebi u postupku poticanja zacjeljivanja rane.
30. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-15, namijenjeno upotrebi u postupku sprječavanja, smanjivanja opasnosti od pojave, ili liječenja artritisa kod osobe kojoj je to potrebno.
31. Postupak inhibitiranja in vitro međudjelovanja između sortilina kojeg se eksprimira na stanici i progranulina, gdje se postupak sastoji u izlaganju stanice koja eksprimira sortilin protutijelu protiv sortilina u skladu s bilo kojim od patentnih zahtjeva 1-15 ili farmaceutski pripravak u skladu s patentnim zahtjevom 21.
32. Postupak u skladu s patentnim zahtjevom 31, pri čemu postupak inhibitiranja međudjelovanja između sortilina kojeg se eksprimira na stanici i progranulina dodatno uključuje snižavanje razine sortilina kojeg se eksprimira na površini stanice.
33. Postupak u skladu s patentnim zahtjevom 31 ili 32, pri čemu postupak inhibitiranja međudjelovanja između sortilina kojeg se eksprimira na stanici i progranulina dodatno uključuje povišavanje izvanstaničnih razina progranulina.
34. Protutijelo namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 23-26, pri čemu se postupak sprječavanja, smanjivanja opasnosti od pojave ili liječenja bolesti, poremećaja, ili ozljede, sastoji u primjeni protutijela na osobi koja ima jednu ili više mutacija u genu koji kodira progranulin.
35. Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 34, pri čemu je osoba heterozigotna za jednu ili više mutacija koje dovode do gubitka funkcije u genu koji kodira progranulin.
36. Protutijelo namijenjeno upotrebi ili postupak u skladu s bilo kojim od patentnih zahtjeva 23-35, pri čemu protutijelo protiv sortilina sadrži dva ili više protutijela protiv sortilina.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862698007P | 2018-07-13 | 2018-07-13 | |
US201962860184P | 2019-06-11 | 2019-06-11 | |
US201962868849P | 2019-06-28 | 2019-06-28 | |
PCT/US2019/041614 WO2020014617A1 (en) | 2018-07-13 | 2019-07-12 | Anti-sortilin antibodies and methods of use thereof |
EP19746306.0A EP3618928B1 (en) | 2018-07-13 | 2019-07-12 | Anti-sortilin antibodies and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20230344T1 true HRP20230344T1 (hr) | 2023-06-09 |
Family
ID=67480375
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20230344TT HRP20230344T1 (hr) | 2018-07-13 | 2019-07-12 | Protutijela protiv sortilina i postupci njihove upotrebe |
Country Status (29)
Country | Link |
---|---|
US (3) | US11396546B2 (hr) |
EP (2) | EP3618928B1 (hr) |
JP (2) | JP7208157B2 (hr) |
KR (2) | KR20230065382A (hr) |
CN (1) | CN111372655A (hr) |
AU (1) | AU2019246837B2 (hr) |
BR (1) | BR112019022666A2 (hr) |
CA (1) | CA3060547A1 (hr) |
CL (2) | CL2021000089A1 (hr) |
CO (1) | CO2021001742A2 (hr) |
CR (1) | CR20210057A (hr) |
DK (1) | DK3618928T3 (hr) |
EC (1) | ECSP21010450A (hr) |
ES (1) | ES2940311T3 (hr) |
FI (1) | FI3618928T3 (hr) |
HR (1) | HRP20230344T1 (hr) |
HU (1) | HUE061841T2 (hr) |
IL (1) | IL270214B1 (hr) |
LT (1) | LT3618928T (hr) |
MX (1) | MX2019012869A (hr) |
PE (1) | PE20210186A1 (hr) |
PH (1) | PH12021550041A1 (hr) |
PL (1) | PL3618928T3 (hr) |
PT (1) | PT3618928T (hr) |
RS (1) | RS64034B1 (hr) |
SI (1) | SI3618928T1 (hr) |
TW (1) | TWI809147B (hr) |
WO (1) | WO2020014617A1 (hr) |
ZA (1) | ZA201906731B (hr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3280441B1 (en) | 2015-04-07 | 2021-09-29 | Alector LLC | Anti-sortilin antibodies and methods of use thereof |
GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
US10894833B2 (en) * | 2017-07-20 | 2021-01-19 | H. Lundbeck A/S | Agents, uses and methods for treatment |
US20200392229A1 (en) * | 2019-06-11 | 2020-12-17 | Alector Llc | Methods of use of anti-sortilin antibodies |
CN116420078A (zh) | 2020-10-14 | 2023-07-11 | 戴纳立制药公司 | 用于治疗和监测额颞痴呆的方法 |
AU2021392039A1 (en) * | 2020-12-02 | 2023-06-29 | Alector Llc | Methods of use of anti-sortilin antibodies |
CN112920264B (zh) * | 2021-02-08 | 2022-07-05 | 武汉大学 | Tdp-43蛋白的o-糖基化突变体及其应用 |
WO2023247754A1 (en) | 2022-06-23 | 2023-12-28 | Draupnir Bio Aps | Bifunctional molecules that selectively induce degradation of extracellular targets in lysosomes |
CN115281146B (zh) * | 2022-07-08 | 2023-06-16 | 山东省农业科学院家禽研究所(山东省无特定病原鸡研究中心) | 一种鸡湿热下利证模型的构建方法 |
CN116731169B (zh) * | 2023-08-09 | 2023-11-03 | 瑞诺元(苏州)生物科技有限公司 | 一种分拣蛋白1特异性的纳米抗体及其应用 |
Family Cites Families (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
CA1338518C (en) | 1987-09-23 | 1996-08-13 | Joyce M. Zarling | Antibody heteroconjugates for the killing of hiv-infected cells |
DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
ES2202310T3 (es) | 1991-12-13 | 2004-04-01 | Xoma Corporation | Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos. |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
ES2304786T3 (es) | 1995-04-27 | 2008-10-16 | Amgen Fremont Inc. | Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados. |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
AU7378096A (en) | 1995-09-28 | 1997-04-17 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
AU782626B2 (en) | 1999-10-04 | 2005-08-18 | Medicago Inc. | Method for regulating transcription of foreign genes |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
ES2528794T3 (es) | 2000-04-11 | 2015-02-12 | Genentech, Inc. | Anticuerpos multivalentes y usos de los mismos |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
JP3523245B1 (ja) | 2000-11-30 | 2004-04-26 | メダレックス,インコーポレーテッド | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 |
ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
US20040119010A1 (en) | 2002-11-01 | 2004-06-24 | The Regents Of The University Of Colorado | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
US8066997B2 (en) | 2002-12-20 | 2011-11-29 | Anders Nykjaer | Modulation of activity of neurotrophins |
EP1682170A2 (en) | 2003-11-07 | 2006-07-26 | Lay Line Genomics SpA | Compositions able to prevent neurodegenerative processes and methods of assaying the same |
MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
JP2008526205A (ja) | 2004-12-31 | 2008-07-24 | ジェネンテック・インコーポレーテッド | Br3に結合するポリペプチド及びその使用 |
US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
US8877714B2 (en) | 2005-06-14 | 2014-11-04 | Raptor Pharmaceutical Inc. | Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof |
CN105330741B (zh) | 2005-07-01 | 2023-01-31 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
US9062126B2 (en) | 2005-09-16 | 2015-06-23 | Raptor Pharmaceuticals Inc. | Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof |
FR2896881B1 (fr) | 2006-01-31 | 2008-04-18 | Biomerieux Sa | Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie |
EP4316465A3 (en) | 2006-03-15 | 2024-04-24 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
CA2651567A1 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
MX2009002893A (es) | 2006-09-18 | 2009-07-10 | Raptor Pharmaceutical Inc | Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap). |
WO2008052016A2 (en) | 2006-10-23 | 2008-05-02 | Columbia University | The sortilin-related receptor sorl1 is functionally and genetically associated with alzheimer's disease |
WO2008076262A2 (en) | 2006-12-15 | 2008-06-26 | Merck & Co., Inc. | Receptor for amyloid beta and uses thereof |
UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
HUE048781T2 (hu) | 2006-12-21 | 2020-08-28 | H Lundbeck As | Proneurotrofinok aktivitásának modulációja |
WO2008086452A2 (en) | 2007-01-10 | 2008-07-17 | Columbia University | Treatment and prevention of alzheimer's disease |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
CL2008002153A1 (es) * | 2007-07-24 | 2009-06-05 | Amgen Inc | Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r. |
EP2193146B1 (en) | 2007-09-14 | 2016-05-25 | Adimab, LLC | Rationally designed, synthetic antibody libraries and uses therefor |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
EP2274327B1 (en) | 2008-04-27 | 2019-03-27 | H. Lundbeck A/S | Crystal structure of human sortilin and uses thereof for identifying ligands to sortilin |
ES2680222T3 (es) | 2008-05-22 | 2018-09-05 | H. Lundbeck A/S | Modulación de los receptores con dominio Vps10p para el tratamiento de la enfermedad cardiovascular |
US20160359907A1 (en) | 2015-06-02 | 2016-12-08 | Vmware, Inc. | Automatically auditing virtual machines for security hardening compliance |
EP2307042B1 (en) | 2008-06-25 | 2014-03-26 | H. Lundbeck A/S | Modulation of the trpv : vps10p-domain receptor system for the treatment of pain |
PE20141433A1 (es) | 2008-07-16 | 2014-10-19 | Inst Research In Biomedicine | Anticuerpos neutralizantes de citomegalovirus humano |
WO2010022175A1 (en) | 2008-08-19 | 2010-02-25 | Yale University | Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin |
WO2010028333A2 (en) | 2008-09-08 | 2010-03-11 | Mayo Foundation For Medical Education And Research | Methods and devices for ligating tubular structures |
CN102439041B (zh) | 2008-12-19 | 2016-05-04 | H.隆德贝克有限公司 | 用于治疗精神和行为障碍的对Vps10p-结构域受体家族的调节 |
FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
WO2011041584A2 (en) | 2009-09-30 | 2011-04-07 | President And Fellows Of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products |
US20130115222A1 (en) | 2010-06-15 | 2013-05-09 | Cornell University | Methods of limiting microvascular damage following acute myocardial ischemia |
EP4219805A1 (en) | 2010-07-16 | 2023-08-02 | Adimab, LLC | Antibody libraries |
US20130336988A1 (en) | 2010-11-17 | 2013-12-19 | New York University | Methods for treating early stage or mild neurological disorders |
AU2012269720B2 (en) | 2011-06-13 | 2015-01-22 | Csl Limited | Antibodies against G-CSFR and uses thereof |
CN103748114B (zh) | 2011-08-23 | 2017-07-21 | 罗切格利卡特公司 | T细胞活化性双特异性抗原结合分子 |
US9822366B2 (en) | 2012-11-02 | 2017-11-21 | The Brigham And Women's Hospital, Inc. | Sortilin 1 is a novel inducer of vascular calcification |
EP2991679A4 (en) | 2013-04-29 | 2016-12-07 | Adimab Llc | POLYSPECIFIC REAGENTS, PROCESS FOR THEIR PREPARATION AND USE |
JP6462680B2 (ja) | 2013-07-09 | 2019-01-30 | アネクソン,インコーポレーテッド | 抗補体因子C1q抗体及びその使用 |
CA2938577A1 (en) | 2014-02-04 | 2015-08-13 | New York University | Progranulin (pgrn) and its derivatives for diagnosis and treatment of lysosomal storage diseases |
EP3105594A1 (en) | 2014-02-12 | 2016-12-21 | H. Lundbeck A/S | Use of sortilin as biomarker for affective/mood disorders |
EP3122765A1 (en) | 2014-03-26 | 2017-02-01 | Goran Landberg | Agents inhibiting granulin for treatment of cancer |
EP3193942B1 (en) | 2014-08-11 | 2020-03-25 | Shire Human Genetic Therapies, Inc. | Lysosomal targeting and uses thereof |
EP3280441B1 (en) | 2015-04-07 | 2021-09-29 | Alector LLC | Anti-sortilin antibodies and methods of use thereof |
US10849992B1 (en) * | 2015-04-07 | 2020-12-01 | Alector Llc | Methods of screening for sortilin binding antagonists |
US20160331746A1 (en) | 2015-05-12 | 2016-11-17 | University Of South Florida | Sortilin-Binding Small Molecules for Increasing Glucose Uptake |
GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
US11390656B2 (en) | 2015-08-04 | 2022-07-19 | New York University | Progranulin (PGRN) fragments and derivatives for treatment or alleviation of lysosomal storage diseases |
US10085969B1 (en) | 2016-02-12 | 2018-10-02 | University Of South Florida | Sortilin binding compounds, formulations, and uses thereof |
US10894833B2 (en) | 2017-07-20 | 2021-01-19 | H. Lundbeck A/S | Agents, uses and methods for treatment |
US11833187B2 (en) | 2017-10-23 | 2023-12-05 | The Brigham And Women's Hospital, Inc. | Materials and methods for extracellular vessicle-associated diseases |
MX2020012518A (es) | 2018-06-18 | 2021-02-16 | Denali Therapeutics Inc | Proteinas de fusion que comprenden progranulina. |
EP3844190A4 (en) | 2018-08-24 | 2022-06-08 | Transfert Plus, S.E.C. | METHODS AND COMPOUNDS FOR TARGETING SORTILIN RECEPTORS AND INHIBITING VASCULOGEN MIMETICISM |
WO2020051624A1 (en) | 2018-09-11 | 2020-03-19 | Grophin Pty Ltd | Methods and compositions for improving recovery from a brain injury |
EP3666281A1 (en) | 2018-12-14 | 2020-06-17 | Insusense ApS | Compositions comprising sortilin-1 |
EP3942049A4 (en) | 2019-03-20 | 2023-10-18 | President And Fellows Of Harvard College | PROGRANULIN AUGMENTATION THERAPY BASED ON ANTI-SENSE OLIGONUCLEOTIDES IN NEURODEGENERATIVE DISEASES |
US20200392229A1 (en) | 2019-06-11 | 2020-12-17 | Alector Llc | Methods of use of anti-sortilin antibodies |
-
2019
- 2019-07-12 CA CA3060547A patent/CA3060547A1/en active Pending
- 2019-07-12 MX MX2019012869A patent/MX2019012869A/es unknown
- 2019-07-12 KR KR1020237014931A patent/KR20230065382A/ko active Application Filing
- 2019-07-12 HU HUE19746306A patent/HUE061841T2/hu unknown
- 2019-07-12 EP EP19746306.0A patent/EP3618928B1/en active Active
- 2019-07-12 BR BR112019022666-4A patent/BR112019022666A2/pt unknown
- 2019-07-12 IL IL270214A patent/IL270214B1/en unknown
- 2019-07-12 WO PCT/US2019/041614 patent/WO2020014617A1/en unknown
- 2019-07-12 FI FIEP19746306.0T patent/FI3618928T3/fi active
- 2019-07-12 AU AU2019246837A patent/AU2019246837B2/en active Active
- 2019-07-12 EP EP22212523.9A patent/EP4212210A1/en active Pending
- 2019-07-12 JP JP2019559056A patent/JP7208157B2/ja active Active
- 2019-07-12 CR CR20210057A patent/CR20210057A/es unknown
- 2019-07-12 CN CN201980002132.9A patent/CN111372655A/zh active Pending
- 2019-07-12 US US16/510,773 patent/US11396546B2/en active Active
- 2019-07-12 PE PE2021000050A patent/PE20210186A1/es unknown
- 2019-07-12 HR HRP20230344TT patent/HRP20230344T1/hr unknown
- 2019-07-12 LT LTEPPCT/US2019/041614T patent/LT3618928T/lt unknown
- 2019-07-12 DK DK19746306.0T patent/DK3618928T3/da active
- 2019-07-12 PL PL19746306.0T patent/PL3618928T3/pl unknown
- 2019-07-12 RS RS20230194A patent/RS64034B1/sr unknown
- 2019-07-12 ES ES19746306T patent/ES2940311T3/es active Active
- 2019-07-12 SI SI201930481T patent/SI3618928T1/sl unknown
- 2019-07-12 TW TW108124750A patent/TWI809147B/zh active
- 2019-07-12 KR KR1020197035737A patent/KR102530517B1/ko active IP Right Grant
- 2019-07-12 PT PT197463060T patent/PT3618928T/pt unknown
- 2019-10-11 ZA ZA2019/06731A patent/ZA201906731B/en unknown
-
2021
- 2021-01-07 PH PH12021550041A patent/PH12021550041A1/en unknown
- 2021-01-12 CL CL2021000089A patent/CL2021000089A1/es unknown
- 2021-02-12 EC ECSENADI202110450A patent/ECSP21010450A/es unknown
- 2021-02-12 CO CONC2021/0001742A patent/CO2021001742A2/es unknown
- 2021-12-13 CL CL2021003327A patent/CL2021003327A1/es unknown
-
2022
- 2022-06-09 US US17/836,644 patent/US20230047941A1/en active Pending
- 2022-06-09 US US17/836,707 patent/US20220348656A1/en active Pending
-
2023
- 2023-01-05 JP JP2023000337A patent/JP2023036932A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20230344T1 (hr) | Protutijela protiv sortilina i postupci njihove upotrebe | |
US11725059B2 (en) | Antibodies targeting B-cell maturation antigen and methods of use | |
US11566071B2 (en) | Nucleic acid molecules encoding anti-GPRC5D antibodies | |
US20210388081A1 (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
HRP20211980T1 (hr) | Protutijela protiv sortilina i postupci njihove upotrebe | |
JP2018517401A5 (hr) | ||
CN102574921B (zh) | 双特异性死亡受体激动型抗体 | |
HRP20220304T1 (hr) | Anti-transferinska receptorska protutijela s prilagođenim afinitetom | |
JP2008541733A5 (hr) | ||
JP2015163068A5 (hr) | ||
US11525005B2 (en) | Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof | |
JP2019527194A5 (hr) | ||
JP2021521881A (ja) | 神経成長因子に対するモノクローナル抗体、並びにそれをコードする遺伝子及びその使用 | |
WO2019195313A1 (en) | Anti-vegf antagonist and pedf agonist constructs and uses thereof | |
WO2019080909A1 (en) | TARGETING THERAPEUTIC ANTIBODY RANKL | |
CN110172099A (zh) | 抗lag-3人源化单克隆抗体分子,抗原结合片段及其医药用途 | |
CN108948193A (zh) | 针对tim-3的抗体分子,抗原结合片段及其医药用途 | |
JPWO2020014617A5 (hr) | ||
WO2022262772A1 (en) | Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof | |
Yélamos | Current innovative engineered antibodies | |
JP2023525298A (ja) | Sirpアルファおよびsirpベータ1抗体、ならびにそれらの使用 | |
JPWO2021068841A5 (hr) | ||
AU2022332499A1 (en) | Fap/cd40 binding molecule and medicinal use thereof | |
NZ732567B2 (en) | Antibodies targeting g-protein coupled receptor and methods of use |